Fig. 3

R848 induces a potent and rapid block to infection with virus bearing a primary HIV-1 isolate envelope glycoprotein. a Monocytes were incubated with 1 µM (dark blue) or 10 µM (light blue) R848 for 24 h and then infected with increasing amounts of Vpx-containing HIV-1 luciferase reporter virus (0.1, 0.3, 1.0 and 3 × 10⁶ cps). Uninfected (mock) and cells infected with virus lacking Vpx (HIV1) were included as controls. b Monocytes from three donors were treated for 24 h with serial dilutions of R848 and then infected with Vpx-containing HIV-1 luciferase reporter virus. c Monocytes were untreated (−) or treated with 10 µM R848 24 h before infection (24 h, blue solid) or at the time of infection (0 h, blue dotted) with Vpx-containing or lacking HIV-1 luciferase reporter virus. d Monocytes from 6 healthy donors were treated for 24 h with R848 (blue squares) or untreated (black dots) and then infected with Vpx-containing HIV-1 luciferase reporter virus bearing a CCR5-tropic transmitted founder envelope glycoprotein (HIV1+ HIV1 env) or uninfected (mock). **p ≤ 0.01 In all 4 experiments a–d luciferase activity was measured 72 h post-infection